{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:56:43Z","timestamp":1781582203613,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.msard.2023.105376","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T22:52:25Z","timestamp":1702335145000},"page":"105376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia"],"prefix":"10.1016","volume":"82","author":[{"given":"Yaneth","family":"Gil-Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Amaya-Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Samac\u00e1-Samac\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00e1n","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7954-1-4","article-title":"A generic model for the assessment of disease epidemiology: the computational basis of DisMod II","volume":"1","author":"Barendregt","year":"2003","journal-title":"Popul. Health Metr."},{"key":"10.1016\/j.msard.2023.105376_bib0002","doi-asserted-by":"crossref","unstructured":"Batra A, Periyavan S, Bajpai V. Plasmapheresis for Neuromyelitis Optica: A Review from the Transfusion Medicine Specialist \u2019 s Perspective. 2018.","DOI":"10.33590\/emjneurol\/10313481"},{"issue":"9","key":"10.1016\/j.msard.2023.105376_bib0003","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1007\/s00415-022-11169-w","article-title":"Patients with multiple sclerosis: a burden and cost of illness study","volume":"269","author":"Battaglia","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105376_bib0004","unstructured":"Biogen Idec Heron Evidence Development. Natalizumab (Tysabri) for the treatment of adults with highly active relapsing remitting multiple sclerosis. 2007."},{"key":"10.1016\/j.msard.2023.105376_bib0005","first-page":"9","article-title":"Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis","author":"Borisow","year":"2018","journal-title":"Rev. Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.105376_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.17151\/hpsal.2020.25.2.6","article-title":"Barreras de acceso del sistema de salud colombiano en zonas rurales: percepciones de usuarios del r\u00e9gimen subsidiado","volume":"25","author":"Bran","year":"2020","journal-title":"Hacia la Promoci\u00f3n en Salud."},{"issue":"2","key":"10.1016\/j.msard.2023.105376_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/IAE.0000000000000717","article-title":"Societal Costs Associated with Neovascular Age-Related Macular Degeneration in the United States","volume":"36","author":"Brown","year":"2016","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.msard.2023.105376_bib0008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0008-4182(05)80070-5","article-title":"Age-related macular degeneration: economic burden and value-based medicine analysis","volume":"40","author":"Brown","year":"2005","journal-title":"Can. J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.msard.2023.105376_bib0009","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14737175.2019.1648210","article-title":"Controversies in the management of neuromyelitis optica spectrum disorder","volume":"19","author":"Bruscolini","year":"2019","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1016\/j.msard.2023.105376_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105376_bib0014","series-title":"Una Naci\u00f3n desplazada, Informe nacional Del Desplazamiento Forzado En Colombia","year":"2015"},{"key":"10.1016\/j.msard.2023.105376_bib0015","unstructured":"Chanatittarat C, Prayoonwiwat N, Siritho S, et\u00a0al. Economic burden of Thai patients with inflammatory demyelinating central nervous system disorders (IDCDs). 2019. doi:10.29090\/psa.2019.04.018.0027 August 25, 2020, http:\/\/cmuir.cmu.ac.th\/handle\/6653943832\/68017."},{"key":"10.1016\/j.msard.2023.105376_bib0016","series-title":"Serie Nacional de Poblaci\u00f3n Por \u00e1rea sexo y Edad Para El Periodo 2005-2070","year":"2021"},{"key":"10.1016\/j.msard.2023.105376_bib0017","unstructured":"Departamento Administrativo Nacional de Estad\u00edsticas (DANE). \u00cdndice de precios al consumidor - IPC https:\/\/www.dane.gov.co\/index.php\/estadisticas-por-tema\/precios-y-costos\/indice-de-precios-al-consumidor-ipc."},{"issue":"3","key":"10.1016\/j.msard.2023.105376_bib0018","first-page":"e23641","article-title":"Neuromyelitis Optica Spectrum Disorder: A Rare Cause of Spinal Cord and Optic Nerve Involvement","volume":"14","author":"Douedi","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2023.105376_bib0019","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.msard.2023.105376_bib0020","article-title":"The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147169","article-title":"Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples","volume":"11","author":"Gao","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0023","first-page":"1","article-title":"Economic burden of multiple sclerosis in a population with low physical disability","volume":"19","author":"Garc\u00eda-Dom\u00ednguez","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.msard.2023.105376_bib0024","unstructured":"Glisson C. Neuromyelitis optica spectrum disorders (NMOSD): Clinical features and diagnosis. Junio 6, 2022, 2022. Updated Noviembre 19, 2021. Accessed Febrero, 2022, 2022. www.uptodate.com."},{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0025","article-title":"Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK","volume":"6","author":"Hakimi","year":"2018","journal-title":"J. Mark. Access. Health Policy"},{"key":"10.1016\/j.msard.2023.105376_bib0026","doi-asserted-by":"crossref","unstructured":"Han L, Hong P, Wan Y, Cai L, Lang Y, Zhou H. Neuromyelitis optica spectrum disorder in Western China impacts employment and increases financial burden in women. Front. Neurol..2058. doi:10.3389\/fneur.2022.973163.","DOI":"10.3389\/fneur.2022.973163"},{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-022-02310-z","article-title":"Health utilities and costs for neuromyelitis optica spectrum disorder","volume":"17","author":"Hughes","year":"2022","journal-title":"Orphanet. J. Rare Dis."},{"issue":"11","key":"10.1016\/j.msard.2023.105376_bib0028","doi-asserted-by":"crossref","first-page":"e1184","DOI":"10.1212\/WNL.0000000000200052","article-title":"Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody\u2013Associated Disease: CHANCENMO Study","volume":"98","author":"H\u00fcmmert","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105376_bib0030","first-page":"1","article-title":"Ministerio de Salud y Protecci\u00f3n Social, Instituto Nacional de Salud-INS, Departamento Administrativo para la Prosperidad Social","volume":"2015","year":"2015","journal-title":"Encuesta Nacional de la Situaci\u00f3n Nutricional - ENSIN"},{"key":"10.1016\/j.msard.2023.105376_bib0031","series-title":"Manual Para La Elaboraci\u00f3n De Evaluaciones Econ\u00f3micas En Salud","year":"2014"},{"key":"10.1016\/j.msard.2023.105376_bib0032","unstructured":"Instituto Nacional de Salud. Estad\u00edsticas de Vigilancia Rutinaria. Junio 6, 2022, 2022. Accessed Junio 3, 2022, http:\/\/portalsivigila.ins.gov.co\/."},{"key":"10.1016\/j.msard.2023.105376_bib0033","first-page":"1","article-title":"2001 - Acuerdo N\u00b0 256 de 2001. Manual de tarifas TARIFAS de la entidad promotora de salud del seguro social EPS-ISS","year":"2001","journal-title":"Consejo directivo del instituto de seguros sociales"},{"issue":"3","key":"10.1016\/j.msard.2023.105376_bib0034","first-page":"M597","article-title":"A simple and accurate method for prescribing plasma exchange","volume":"36","author":"Kaplan","year":"1990","journal-title":"ASAIO Trans."},{"issue":"6","key":"10.1016\/j.msard.2023.105376_bib0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/ane.13411","article-title":"Socioeconomic consequences of multiple sclerosis-A systematic literature review","volume":"143","author":"Kavaliunas","year":"2021","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0036","first-page":"137","article-title":"Therapeutic plasma exchange in the neurologic intensive care setting recommendation for clinical practice","volume":"51","author":"Kes","year":"2012","journal-title":"Acta Clin. Croat."},{"issue":"22","key":"10.1016\/j.msard.2023.105376_bib0037","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.105376_bib0038","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","article-title":"Evaluating the economic burden of relapses in neuromyelitis optica spectrum disorder: a real-world analysis using german claims data","volume":"11","author":"Knapp","year":"2022","journal-title":"Neurology and Therapy"},{"key":"10.1016\/j.msard.2023.105376_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103332","article-title":"Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies","volume":"57","author":"Levy","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105376_bib0041","series-title":"(23, diciembre, 1993). Por la Cual Se Crea El Sistema De Seguridad Social Integral y Se Dictan Otras Disposiciones","first-page":"1","year":"1993"},{"key":"10.1016\/j.msard.2023.105376_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105376_bib0043","unstructured":"Ministerio de Salud y de la Protecci\u00f3n Social (MSPS). Bodega de datos Sispro - Cubo de Registro Individual de Prestaciones de Servicios de Salud (RIPS)."},{"key":"10.1016\/j.msard.2023.105376_bib0045","article-title":"Cubo de datos: MIPRES - Bodega de datos Sispro","volume":"18","year":"2022","journal-title":"Enero"},{"key":"10.1016\/j.msard.2023.105376_bib0046","unstructured":"Ministerio de Salud y Protecci\u00f3n Social. Cubo de Suficiencia. . Accessed Enero del 2022."},{"key":"10.1016\/j.msard.2023.105376_bib0047","unstructured":"Ministerio de Salud y Protecci\u00f3n Social. Bodega de datos Sispro: Cubo de incapacidades."},{"key":"10.1016\/j.msard.2023.105376_bib0048","first-page":"1","volume":"2018","year":"2018"},{"key":"10.1016\/j.msard.2023.105376_bib0049","unstructured":"Ministerio del Trabajo. Fuente de informaci\u00f3n laboral de Colombia - FILCO: Estad\u00edsticas. 2021."},{"key":"10.1016\/j.msard.2023.105376_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103677","article-title":"Prevalence of neuromyelitis optica spectrum disorder in antioquia between 2016 and 2018","volume":"60","author":"Monsalve Munoz","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.105376_bib0051","first-page":"429","article-title":"Quantifying the burden of disease: the technical basis for disability-adjusted life years","volume":"72","author":"Murray","year":"1994","journal-title":"Bull. World Health Organ."},{"issue":"9","key":"10.1016\/j.msard.2023.105376_bib0052","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105376_bib0053","unstructured":"Observatorio del Mercado de Trabajo. Definiciones b\u00e1sicas. https:\/\/www.minsalud.gov.co\/trabajoEmpleo\/Paginas\/definiciones.aspx."},{"key":"10.1016\/j.msard.2023.105376_bib0054","unstructured":"Orphanet. Neuromyelitis optica spectrum disorder. Junio 6, 2022, 2022. Updated Julio, 2021. Accessed Junio 5, 2022, https:\/\/www.orpha.net\/."},{"issue":"2","key":"10.1016\/j.msard.2023.105376_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2023.105376_bib0056","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.105376_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105376_bib0059","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2023.105376_bib0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/1352458520910499","article-title":"Data harmonization for collaborative research among MS registries: a case study in employment","volume":"27","author":"Salter","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.105376_bib0061","unstructured":"SECOP II (CPAP). Comunicaci\u00f3n de aceptaci\u00f3n de oferta convocatoria m\u00ednima cuantia MI 0044-DMORI-2021.\u00a0 https:\/\/community.secop.gov.co."},{"key":"10.1016\/j.msard.2023.105376_bib0062","article-title":"Formato de presentaci\u00f3n de propuesta econ\u00f3mica: Selecci\u00f3n abreviada de menor cuantia - SAMC - BS - 002 de 2021","volume":"30","year":"2022","journal-title":"Enero"},{"key":"10.1016\/j.msard.2023.105376_bib0063","article-title":"Contrato de suministro N\u00b0669-DIGSA-DMSOC-2021","volume":"30","year":"2022","journal-title":"Enero"},{"key":"10.1016\/j.msard.2023.105376_bib0064","doi-asserted-by":"crossref","unstructured":"SISMED-Sistema de Informaci\u00f3n de Precios de Medicamentos. Consulta P\u00fablica de Precios de Medicamentos en la Cadena de Comercializaci\u00f3n - Circular 2 de 2010 December 16th, 2021. https:\/\/web.sispro.gov.co.","DOI":"10.11565\/oe.vi163.437"},{"issue":"5","key":"10.1016\/j.msard.2023.105376_bib0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105376_bib0067","first-page":"177","article-title":"International Panel for NMO Diagnosis 2015","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Neurology"},{"key":"10.1016\/j.msard.2023.105376_bib0068","series-title":"WHO Methods and Data Sources For Global Burden of Disease Estimates 2000-2019","year":"2020"},{"key":"10.1016\/j.msard.2023.105376_bib0069","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"22","key":"10.1016\/j.msard.2023.105376_bib0070","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2023.105376_bib0071","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:09:59Z","timestamp":1761901799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823008763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":62,"alternative-id":["S2211034823008763"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105376","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105376"}}